BC002199 Inhibitors
Chemical inhibitors of BC002199 can affect the protein's activity through various modes of action. Staurosporine, a broad-spectrum kinase inhibitor, blocks the ATP binding site of BC002199, which is essential for its kinase activity. This prevents BC002199 from phosphorylating its substrates, effectively shutting down its catalytic function. Similarly, Bisindolylmaleimide I targets protein kinase C (PKC), and if BC002199's activity is regulated by or involves PKC in its pathway, Bisindolylmaleimide I's action would result in BC002199 inhibition by preventing PKC-mediated activation or phosphorylation of BC002199.
Rapamycin, which specifically targets mTOR kinase, and LY294002, a PI3K inhibitor, can inhibit BC002199 indirectly by acting upstream within the same pathway. If BC002199 operates downstream of mTOR or PI3K, these inhibitors would block the activation signals that BC002199 requires for its function. Wortmannin, another PI3K inhibitor, also acts covalently to inhibit PI3K, which can lead to the inhibition of BC002199 if it is downstream of this pathway. In the MAPK/ERK pathway, PD98059 and U0126, both MEK inhibitors, prevent the activation of kinases downstream of MEK, including BC002199 if it is part of this signaling cascade. SB203580, which selectively inhibits p38 MAP kinase, and SP600125, a JNK pathway inhibitor, work in a similar fashion by targeting kinases upstream of BC002199, leading to its functional inhibition if it is reliant on these pathways for activation. Additionally, the tyrosine kinase inhibitors Imatinib and Gefitinib, which target Bcr-Abl/c-Kit and EGFR respectively, can decrease the activity of BC002199 by inhibiting upstream kinases that regulate BC002199. Lastly, Triciribine, by specifically inhibiting Akt kinase, can suppress the activity of BC002199 if its function is controlled by the PI3K/Akt signaling axis. Each inhibitor, by targeting specific kinases or pathways, can modulate the activity of BC002199 depending on its position and role within these cellular signaling networks.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
This alkaloid acts as a potent inhibitor of protein kinases. Considering BC002199 is a kinase, Staurosporine inhibits its kinase activity by blocking its ATP binding site, thereby preventing phosphorylation events that BC002199 would normally catalyze. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR, a protein kinase involved in cell growth and proliferation. If BC002199 is involved in these pathways through mTOR signaling, rapamycin's inhibition of mTOR would consequently inhibit the downstream effects of BC002199 that are mTOR-dependent. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, which is upstream of many kinase pathways. If BC002199 operates downstream of PI3K, inhibiting PI3K with LY294002 would inhibit the activation and functionality of BC002199. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 indirectly inhibits the activation of downstream kinases. If BC002199 is a kinase that acts downstream of MEK, then its kinase activity would be inhibited as a consequence of MEK inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a covalent inhibitor of PI3K. If BC002199 functions downstream of the PI3K pathway, inhibition of PI3K by wortmannin would result in the functional inhibition of BC002199 by preventing its activation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which inhibits the MAPK/ERK pathway. Inhibition of this pathway by U0126 would prevent the activation of any downstream kinases that are dependent on this pathway for activation, including BC002199 if it is a part of this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase. If BC002199's activity is contingent on the p38 MAPK pathway, then the inhibition of this pathway by SB203580 would result in the functional inhibition of BC002199. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the stress-activated protein kinase pathway. If BC002199 is a kinase that acts downstream of JNK, inhibition of JNK by SP600125 would prevent the activation of BC002199, resulting in its functional inhibition. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets Bcr-Abl and c-Kit. If BC002199 is a tyrosine kinase that is part of the same pathway or is regulated by Bcr-Abl or c-Kit, imatinib would inhibit the function of BC002199 by inhibiting the kinases that regulate it. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. If BC002199 is a tyrosine kinase within the EGFR signaling pathway, inhibition of EGFR by gefitinib would lead to a decrease in BC002199's tyrosine kinase activity by preventing its phosphorylation and subsequent activation. | ||||||